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The ATP binding site of mitochondrial creatine kinase from chicken heart has been studied by modifying the purified enzyme with a r4C-labelled 
ATP analogue, ClRATP, in which the reactive label was covalently bound to the y-phosphote group of ATP. The modified enzyme was digested 
by pepsin, and a single radioactive nonapeptide was isolated by HPLC. Amino acid analysis and direct sequence determination revealed that the 
isolated peptide corresponds to amino acids 33.5-343 within the C-terminal region of MCCK, this peptide being highly preserved throughout evolu- 
tion. Asp-335 is very hkely the site of modification by ClRATP. The specificity of the ATP analogue for the active site of creatine kinase was 
demonstrated by the inhibition of the enzymatic activity of MI-CK by ClRATP and by the prevention of this inhibition bij ADP. 
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I. INTRODUCTION 
Creatine kinase (CK; EC 2.7.3.2) catalyzes the rever- 
sible transfer of the y-phosphate group of ATP to 
creatine to yield phosphorylcreatine and ADP. CK is 
found primarily in tissues with high and fluctuating 
energy demands like brain, heart, skeletal muscle, sper- 
matozoa, and retina where it serves to replenish the high 
energy phosphate pools (ATP and phosphoryl~reatine) 
and to ensure effective energy transport from the sites 
of production (mitochondria, glycolysis) to the sites of 
utilization (kinases, ATPases; for a review see [I]). In 
higher vertebrates, four different subunit isoforms of 
CK are known, two of which are localized in the 
cytoplasm (M- and B-CK) and two in the mitochondrial 
intermembrane space (Mi,- and Mib-CK) [1,2], 
Although the guanidine and nucleotide substrates are 
known to bind to two adjacent sites on the CK molecule 
thus enabling a direct ‘in line’-transfer of the phosphate 
group from one substrate to the other [3,4] and 
although 19 amino acid sequences of creatine kinase 
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isoenzymes from a variety of species (Schistosoma man- 
soni, sea urchin, Torpedo, frog, chicken, mouse, rat, 
rabbit, dog, and man) are known up to date [5-241 (see 
Table I), little information is currently available on the 
amino acid residues involved in substrate binding and 
catalysis. A large number of thiol reagents were shown 
to modify one very reactive cysteine residue per subunit 
(Cys-278; numbering according to chicken h&&K 
1191) with a concomitant loss of enzymatic activity (for 
reviews see [25,26]). Cys-278 is therefore assumed to be 
essential for the reaction mechanism and is conserved in 
all 19 sequences. Using 1 ,Sdifluoro-2,4_dinitrophenol 
as a bifunctional crosslinker, Mahowald [27] 
demonstrated that in native CK Cys-69 and Lys-191 are 
in close proximity to Cys-278. Like Cys-278, both 
Cys-69 (found in 14 of 19 sequences; in the Mi-CK 
isoenzymes, Cys is replaced by Met) and Lys-191 
(found in 18 of 19 sequences) are located in sequence 
stretches that are highly conserved throughout evolu- 
tion. NMR experiments and inhibition studies with 
reagents pecific for particular amino acids have reveal- 
ed that, in addition to the residues mentioned above, a 
lysine, arginine, histidine, tryptophan as well as an 
aspartate or glutamate residue are also at or near the ac- 
tive site of creatine kinase [25,26,28,29]. However, the 
precise location of these amino acids within the primary 
structure has not been determined. 
Abbreviuiions: CK, creatine kinase; M&&K, mitochondrial isoen- 
zyme of creatine kinase from chicken heart; ClRATP, y-[4-(N-2- 
c~oroe~yl-~methyl~no~lbenzyla~de adenosine triphosphate; 
BSA, bovine serum albumin 
In this study, the substrate binding site of mitochon- 
drial creatine kinase from chicken heart (Mib-CK) was 
probed with ClRATP, an ATP analogue which had 
been previously used successfully for the specific labell- 
ing of the active site of Na+/K+-ATPase [30]. 
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Fig. 1. Structural formula of ClRATP (A) and ATP-y-p-azidoanilide (B) with the reactive label attached to the -r-phosphate group of ATP. 
2. MATERIALS AND METHODS 
CIRATP was synthesized as described by Dzhand~ugasyan et al. 
1311. Pepsin was purchased from Worthington Biochemical Corp. 
(Freehold, NJ, USA), phosphorylcr~tine from Calbiochem 
(Lucerne, Switzerland), and ADP from Boehringer-Mann~eim 
(FRG). All chemicals used for sequencing and amino acid analysis 
were from Applied Biosystems (ABI), (Foster City, CA, USA). 
Mitochondrial creatine kinase (Mib-CK) was isolated from chicken 
cardiac muscle according to [32]. 
2.1. Inhibition of Mi-CK activity by CIRATP 
The inhibition of Mi&K from chicken heart by ClRATP was per- 
formed essentially as described by Ovchinnikov et al. 1301. Mib-CK 
was dialysed extensively against 20 mM Tris-HCl, pH 7.5 and then in- 
cubated at a protein concentration of I.5 mglml and at 37°C with 
0.25 mM QRATP for the indicated periods of time. At the end of the 
incubation, the CK activity was imm~iately measured by the pH-stat 
method at 25°C and pH 7.0 as previously described [33] with 20 mM 
T 
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Fig. 2. Inactivation of mitochondrial creatine kinase from chicken 
heart (Mi&K) by ClRATP. Mib-CK was incubated at 25’C and pH 
7.5 for the indicated periods of time. ( A ) In the absence of CIRATP; 
( n ) in the presence of 0.25 mM ClRATP; (0) in the presence of 0.25 
mM ClRATP + 4 mM ADP. CK activity was measured by the pH- 
stat method. All data points are given as mean 4 SD of 3 
measurements. 
HCl as the titrating agent, but without BSA in the assay mixture. In 
control experiments, Mib-CK was incubated under identical condi- 
tions without ClRATP or, after a prein~ubation with 4 mM ADP for 
I h on ice, with ClRATP in the presence of 4 mM ADP. 
2.2. LabeIling and digestion of ~itochondf~a~ creatine kinase 
Mib-CK was labelled with [‘%]ClRATP (with the radioactivity in 
the benzyl group; see Fig. IA) by incubating the enzyme for 30 min 
at 37°C in 20 mM Tris-HCl buffer, pH 7.5. The concentration of the 
protein was 1 mg/ml and that of the reagent 0.2 mM. The extent of 
incorporation of the radioactive label was 66%. Cold reagent was 
then added to yield a final concentration of 1 mM ClRATP, and the 
protein/reagent mixture was incubated for a further 30 min to in- 
crease the yield of labelled product. 
Since the ester bond formed between the label and the protein was 
known from previous work on the Na+/K+-ATPase 1301 to be very 
labile, especially above pH 4.0, a pepsin digest of the modified en- 
zyme was carried out as follows: the protein was precipitated with 
10% TCA and washed several times with the same solution to remove 
unbound label. The final peliet was dissolved in 2% formic acid and 
subsequently digested with pepsin for 2 h at 37”C, using a ratio of 
protease:protein of 1:lOO (w/w). The digestion was stopped by 
heating the solution to 100°C for 2 min and then injecting the solution 
onto the HPLC device. A gradient was run over 30 min from O-50% 
n-propanol in 10 mM tetraethyl ammonium acetate, pH 5.5 (see Fig. 
2). A 3OOA C-8 (2.1 x 100 mm) ABI reversed phase column was used. 
Fractions were collected every 40 s, and a 5% aliquot of each fraction 
was used for scintillation counting in a Beckman LSl80 1 scintillation 
counter. The peak containing the radioactivity was then repurified on 
a C-18, 1.0 x 250 mm microbore column using a gradient of 
acetonitrile with 0.15% TFA to yield a single homogeneous peak. 
From this material, 20% was used for amino acid analysis (ABI model 
420A with on-tine PTC detection) and the rest was used directly for 
amino acid sequencing (ABI model 470A with on-line PTH detec- 
tion). 
3. RESULTS 
To ascertain that ClRATP, the structural formula of 
which is shown in Fig. lA, binds to the nucleotide bin- 
ding site of mitochondrial creatine kinase, the effect of 
0.25 mM of the ATP analogue on M&CR activity was 
investigated (Fig. 2). Within one hour, M&-CR was in- 
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Fig. 3. Reversed phase chromatography profile of the pepsin digest of 
Mib-CK labelled with [r4C]CIRATP. The labelling, pepsin digestion, 
and separation of the peptides obtained were performed as described 
in section 2. (-) Absorbance at 206 nm; (- + --- + -) radioactivity. 
activated to more than 95%. Preincubation with 4 mM 
ADP, which is expected to compete for the nucleotide 
binding site, drastically reduced the inactivation rate 
and thus showed that the covalent modification by 
ClRATP is not due to unspecific labelling, but to selec- 
tive interaction of the label with the substrate binding 
site. 
In order to identify the position of the amino acid 
residue(s) modified by the ATP analogue, Mib-CK 
Table I 
Comparison of amino acid residues 332-346 from all known CK se- 
quences (numbering of amino acids according to chicken Mit,-CK) 
332 * 346 
(1) S NLDRMGRS&LVQ 
(2) S NI DRI GRSEVELVQ 
(3) S NLDRLGKSEVELVQ 
(4) S NADRLGFSEVELVQ 
(5) S NADRLGFSEVEQVQ 
(6) S NADRLGSSEVEQVQ 
(7) S NADRLGFSEVEQVQ 
(8)a S NADRLGFSEVEQVQ 
(9): 
S NKRRLGLTELDAVT 
S NLDRLGTSEVQQVQ 
b S NLDRLGSSEVQQVQ 
C S NSDRI GFSEVHLVQ 
Amino acid residue 335, which was labelled by ClRATP in Mib-CK, 
is written in bold letters. The three acidic residues (Asp and Glu) con- 
served throughout evolution are marked by stars. The CIRATP- 
labelled Mib-CK nonapeptide obtained by pepsin digestion is 
underlined. 
(1) chicken leg muscle Mi-CK (Mib-CK) [19]; (2) human heart Mi-CK 
[22]; (3) human placenta Mi-CK [20]; (4) chicken [14], rabbit [12], rat 
[lo], human [17,18], and dog B-CK [15], Xenopus CK-IV [21]; (5) 
chicken M-CK [7]; (6) rabbit IS], rat [a], mouse Ill], human [16], and 
dog M-CK [13]; (7) Torpedo mormorata CK [9] and Torpedo culifor- 
nicu CK [8]; (8) two corresponding regions (a,b) within the amino acid 
sequence of the ATP-guanidino phosphotransferase (showing CK ac- 
tivity) of Schktosoma mansoni, where a duplicated gene is expressed 
as a contiguous dimer [23]; (9) three corresponding regions (a,b,c) 
within the amino acid sequence of the creatine kinase from sea urchin 
spermatozoa tails, where a triplicated gene is expressed as contiguous 
CK trimer [24]. 
labelled with [‘4C]ClRATP was digested by pepsin. 
Separation of the peptide mixture by HPLC revealed a 
single peak of radioactivity (Fig. 3) which upon 
rechromatography proved to contain only one peptide 
species (not shown). The yield of radioactively labelled 
peptide, based on the amount of radioactivity recovered 
from the TCA-washed Mi-CK pellet before digestion, 
was 18%. The rest of the radioactive label was lost dur- 
ing purification of the peptide due to instability of the 
ester linkage between the ATP analogue and Mib-CK. 
Sequence analysis revealed the radioactively labelled 
peptide to correspond to amino acid residues 335-343 
of Mib-CK [ 191: Asp-Arg-Met-Gly-Arg-Ser-Glu-Val- 
Glu. Most of the radioactivity was recovered in the first 
cycle of sequencing, indicating either that the ester 
bond was completely unstable under sequencing condi- 
tions, or more likely that Asp-335 was the site of label- 
ling. This is supported by the fact that the yield of Asp 
was 600 pmol, whilst the other 8 amino acids were 
detected at the nmol level. Since the modified aspartate 
would not be detected under the HPLC conditions us- 
ed, the labelling therefore very probably occurred at 
Asp-335. Amino acid analysis of the radioactive peptide 
revealed the same composition as that derived from se- 
quencing. As can be seen from Table I, the amino acid 
sequence around Asp-335 is highly conserved through- 
out evolution confirming its structural and/or func- 
tional importance for the CK molecule. 
4. DISCUSSION 
Inspection of all 19 CK sequences known up to date 
reveals that none of the criteria used for identifying 
nucleotide binding domains in proteins is applicable to 
CK. There is no glycine-rich bend (GxggxG) which 
forms the phosphate binding loop in a variety of en- 
zymes [34], and there is no P-sheet ending in an o-helix 
which could be a candidate for a specific ATP binding 
site [34,35]. By using ClRATP as a label for the active 
site of Mib-CK, more information was sought about the 
amino acid residues involved in substrate binding in the 
hope of finding homologies to other nucleotide or 
creatine binding proteins. 
The ClRATP derivative is such that the reactive label 
is attached to the y-phosphate group of ATP. When the 
nucleotide substrate is bound to the CK molecule, this 
is the position usually occupied by a Mg2 + ion co- 
ordinating the oxygen atoms of the (Y-, p- and y- 
phosphate groups of ATP [26]. Because the label at- 
tached to the y-phosphate group in CIRATP is rather 
large and bulky, two possibilities for the attachment site 
of the ATP analogue must be considered. 
(i) ClRATP binds to an amino acid residue involved 
in the binding of the Mg2+ ion. Support for this inter- 
pretation comes from structural comparisons with 
adenylate kinase, the crystal structure of which is 
known [36]. NMR studies with Cr3 + -ATP as the 
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nucleotide substrate suggested that in adenylate kinase 
the metal ion coordinated to the ATP comes into close 
contact with His-189 [37]. This histidine is part of an (Y- 
helix between residues lm and 194 which in addition 
contains an acidic region. It seems very reasonable to 
assume that the aspartate and glutamate residues in this 
acidic region are involved in the binding of the metal 
ion. The region of Mib-CK labelled by CIRATP would 
be analogous to the acidic region of adenylate kinase 
and could therefore be the coordination site for the 
Mg2 + ion bound to the ATP. This interpretation is fur- 
ther corroborated by the high degree of conservation 
throughout evolution of the three aspartate and 
glutamate residues within the Mib-CK peptide labelled 
by ClRATP (Table I, marked by stars). 
(ii) ClRATP binds to an amino acid residue involved 
in the binding of the guanidinium substrate. Since pH 
studies showed that an aspartate or glutamate residue 
of CK is involved in the binding of creatine 1291 and 
since affinity labelling of CK with epoxycreatine led to 
the modification of an aspartate or glutamate residue 
[28], Asp-335 might be involved in the binding and pro- 
per orientation of the creatine molecule for catalysis. 
Asp-335 might bind to one of the two nitrogen atoms of 
the guanidinium group, attract the positive charge of 
this group and therefore render the other nitrogen atom 
more nucleophilic (for a discussion see [29]). Unfor- 
tunately, comparison of the labelled peptide around 
Asp-335 of Mib-CK with creatine amidinohydrolase, 
the only creatine binding protein besides CK for which 
the primary (and tertiary) structure is known [38], 
revealed no significant homology. The additional fact 
that the two enzymes have no secondary structure pat- 
tern in common indicates that the creatine binding sites 
of CK and creatine amidinohydrolase are likely to be 
markedly different. 
Although both interpretations must be viewed as ten- 
tative, they can serve as working models for future 
mutagenesis tudies which, together with work now in 
progress on the analysis of recently obtained Mib-CK 
crystals [39,40], are expected to bring about conclusive 
evidence for or against these two possibilities. 
Using ATP--y-p-azidoanilide, a photoactivatable 
ATP analogue structurally very similar to ClRATP 
(Fig. lB), Vandest et al. [41] were able to specifically 
label one cysteine residue per subunit of rabbit muscle 
M-CK, seemingly Cys-278. Both Cys-278 and Asp-335 
are therefore very likely to be at or near the substrate 
binding site, probably in close proximity to each other. 
This interpretation is in accordance with the NMR and 
EPR experiments of McLaughlin et al. [4] who 
demonstrated that the distance between a nitroxide 
label attached to Cys-278 and the nucleotide and 
guanidine substrates is only 7-8 A. 
The findings that Cys-278 [25,26], Cys-69, Lys-191 
[27], and Asp-335 (this study) all are near the active site 
of creatine kinase indicates that the substrate binding 
142 
site of CK is formed by a complex refolding of the 
polypeptide chain. The structural and/or functional im- 
portance of the four amino acid residues for CK activity 
is further corroborated by the high degree of sequence 
conservation around each of these residues (for 
Asp-335 see Table I). Interestingly, digestion of M-CK 
[42,43] as well as Mib-CK (M. Wyss, unpublished 
results) with proteinase K, which selectively cleaves the 
polypeptide chain between Ala-328 and Ala-329 in M- 
CK and between Ala-324 and Val-325 in Mib-CK, 
respectively, leads to complete inactivation of the CK 
isoenzymes, although the two parts of the molecule re- 
main associated with each other. This further indicates 
that the C-terminal 50 amino acid residues of the CK 
molecule in general and Asp-335 in particular are essen- 
tial for the enzymatic mechanism. 
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